Clinofibrate - CAS 30299-08-2
Catalog number:
30299-08-2
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C28H36O6
Molecular Weight:
468.58
COA:
Inquire
Targets:
HMGCR
Description:
Clinofibrate inhibits hydroxymethylglutaryl coenzyme A reductase (HMGCR) with IC50 of 0.47 mM, is a lipid-lowering agent used for controlling high cholesterol and triacylglyceride levels in the blood.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Clinofibrate
MSDS:
Inquire
1.[Usefulness of examination of the cholesterol versus triglyceride ratio for lipoprotein fractions in a patient with marked hyper-triglyceridemia].
Sato I1, Hyakuta M, Hayashi F, Mukai M, Kondo S, Maeda E, Kumagai S. Rinsho Byori. 2002 Oct;50(10):987-91.
A patient consulted the emergency room with acute pancreatitis, hypertriglyceridemia, and diabetes mellitus, and was later admitted to the hospital. Serum levels of total cholesterol(TC) and total triglyceride (TTG), and the cholesterol(Chol) versus triglyceride(TG) ratio(Chol/TG) for lipoprotein fractions were examined periodically during the course of treatment using Chol/Trig Combo, which identifies Chol and TG by differential staining. On admission, the patient's TTG, pancreatic amylase and glucose levels were 4020 mg/dl, 2012 IU/l, and 242 mg/dl, respectively. Clinofibrate administration resulted in a decrease in Chol and TG values for all fractions. However, the Chol/TG ratios were unchanged(HDL of 0.2 to 0.4, VLDL of approximately 0.13, and LDL of 0.1 to 0.2: Reference values from 103 healthy students were as follows: HDL 5.8 +/- 2.0, VLDL 0.39 +/- 0.1, and LDL 4.9 +/- 1.3[Mean +/- SD].). During clinofibrate treatment, TC and TG values gradually increased.
2.4,4'-(Cyclo-hexane-1,1-di-yl)diphenol methanol solvate.
Shuai J, Liu Y, Liu M, Liu D. Acta Crystallogr Sect E Struct Rep Online. 2009 Jan 10;65(Pt 2):o269. doi: 10.1107/S1600536809000427.
The title compound, crystallized as a methanol solvate, C(18)H(20)O(2)·CH(3)OH, is an inter-mediate in the synthesis of the anti-lipidemic agent clinofibrate. Mol-ecules are packed together with the methanol solvent molecule via two O-H⋯O hydrogen bonds. The third O-H⋯O hydrogen bond is between neighboring 4,4'-(cyclo-hexane-1,1-di-yl)diphenol mol-ecules. The dihedral angle between two benzene rings planes is 81.69 (6).
3.Influence of fibrates on ethanol metabolism in rats.
Hayashi K1. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2000 Oct;35(5):306-20.
The fibrates are widely used for the reduction of high triglyceride levels. The fibrates act as the peroxisome proliferator-activated receptor alpha ligands to regulate the transcription of large number of genes that affect lipoprotein and fatty acid metabolism. The male rats of Wistar strain, simfibrate-treated (100 mg/kg, 200 mg/kg) or clinofibrate-treated (50 mg/kg, 100 mg/kg), were given ethanol (2 g/kg) orally. Blood ethanol levels on the simfibrate groups (100 mg/kg, 200 mg/kg) were significantly lower than the control groups (p < 0.01). The clinofibrate groups (100 mg/kg) were also lower than the controls (p < 0.05). The fatty acid beta-oxidation activity of liver peroxisome in simfibrate-treated (200 mg/kg) or clinofibrate-treated (100 mg/kg) rats for single administration (2.5 hours before the measurement) and twice administrations (20 and 1 hours before the measurement) were assayed. The activity ratio was 168% in simfibrate (p < 0.
4.A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin.
Shiina Y1, Homma Y, Oguma T, Fusegawa Y, Ozawa H, Handa S, Tanabe T. Tokai J Exp Clin Med. 2005 Sep;30(3):149-55.
Low density lipoprotein (LDL)-apheresis is a useful tool for the treatment of familial hypercholesterolemia (FH) with coronary artery disease (CAD). However, it gives economic, physical and mental burdens for the patients. We reports a case of FH in whom LDL-apheresis treatment was seceded with drug treatment with a potent statin and bile acid-sequestering resin. A 54-year-old woman was admitted for evaluation of atherosclerotic lesion after 4 years of LDL-apheresis and 1 year of drug medication with a potent statin, atorvastatin and resin, cholestimide with coronary angiography. She had been diagnosed as heterozygous FH when she was 46 years old. Oral medication was initiated at the outpatient clinic. LDL-cholesterol (C) level was not successfully controlled despite the administration of a statin, pravastatin, a fibrate, clinofibrate and probucol at maximum doses Concomitantly. Therefore, as combination therapy, LDL-apheresis was introduced in May 1997.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 30299-08-2 Clinofibrate

Quick Inquiry

Verification code

Featured Items